Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Round Two: Mevacor Switch Will Need To Quiet Undertreatment Questions

This article was originally published in The Tan Sheet

Executive Summary

One of J&J/Merck's key challenges in pursuing an OTC switch for Mevacor (lovastatin) will be convincing FDA that labeling can alleviate the risk of undertreating high cholesterol

You may also be interested in...

J&J/Merck Developing Mevacor 20 Mg As OTC For Moderate Risk Group

J&J/Merck's second try at an Rx-to-OTC switch for Mevacor (lovastatin) involves a 20 mg dose targeted at a moderate to intermediate risk group, according to VP-Regulatory & Scientific Affairs Edwin Hemwall, PhD

Lipitor v. Pravachol Studies Raise Questions On Utility Of OTC-Dose Statins

Two recently published clinical trials involving statins that report a clear and substantial benefit from intensive LDL-cholesterol lowering versus moderate reduction may dampen prospects for switching the drugs OTC in the U.S

Pravachol Low Drug Interaction Profile Deemed Favorable During OTC Review

The drug interaction profile of Bristol-Myers Squibb's Pravachol may make the cholesterol-lowering agent a more attractive OTC switch candidate than Merck's Mevacor, FDA advisory committee members suggested.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts